Eculizumab (Soliris®)

DRUG3 trials

Sponsors

Alexion Pharmaceuticals, Inc., Massachusetts General Hospital, Bisirna Therapeutics (Suzhou) Co., Ltd.

Conditions

NMOSDParoxysmal Nocturnal Hemoglobinuria, PNHShiga-like Toxin-producing Escherichia Coli

Phase 2

Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

CompletedNCT01410916

Alexion Pharmaceuticals, Inc.Shiga-like Toxin-producing Escherichia Coli

Start: 2011-07-31End: 2012-06-30Updated: 2013-04-05

Phase 3

A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Not yet recruitingNCT07816237

Bisirna Therapeutics (Suzhou) Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria, PNH

Start: 2026-10-29End: 2029-12-31Target: 70Updated: 2026-09-11

Phase 4

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Not yet recruitingNCT07010302

Massachusetts General HospitalNMOSD

Start: 2026-08-01End: 2030-05-01Target: 540Updated: 2026-08-31